- €771.69m
- €704.43m
- $376.13m
US FDA approves Pharming's immune disorder drug (updated)
US FDA approves Pharming's immune disorder drug
Brief: Pharming Announces FDA Approval Of Joenja As First And Only Treatment Indicated For APDS
Brief: Pharming Group FY Revenues Rises 3% To $205.6 Mln
Factbox: Global firms with exposure to collapsed SVB
Brief: Pharming Group Expects To Have Access To Its $19 Million Deposit At SVB UK
Dutch biotech Pharming expects to have full access to funds at SVB
Brief: Pharming Group Expects Full Access Today To Its Cash On Deposit At Silicon Valley Bank
Dutch biotech Pharming says it held $45 mln in collapsed SVB
Pharming falls as leniolisib's review loses accelerated tag in Europe
Brief: Pharming Provides Update On EMA Review Of Leniolisib
Brief: Pharming Announces Positive Interim Analysis Data From Leniolisib's Open-Label Extension Study
Brief: Pharming Publishes Data From Phase 3 Study Of Leniolisib
Brief: Pharming Announces European Medicines Agency (EMA) Validates Its Marketing Authorisation Application Under Accelerated Assessment For Leniolisib
Brief: Pharming Group Nine-Month Revenues Up At $151.0 Mln
Brief: Pharming Submits Marketing Authorisation Application To The EMA For Leniolisib
US FDA Acceptance For Priority Review Of New Drug Application For Leniolisib
Brief: Pharming Group H1 Net Profit Rises To $19.2 Million
Brief: Pharming Gets EMA Accelerated Assessment For leniolisib